Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics

Hiroyuki Uchida; Ariel Graff-Guerrero; Benoit H. Mulsant; Bruce G. Pollock; David C. Mamo

doi:10.1016/j.schres.2008.12.022

Long-term stability of measuring D₂ receptors in schizophrenia patients treated with antipsychotics

Hiroyuki Uchida, Ariel Graff-Guerrero, Benoit H. Mulsant, Bruce G. Pollock, David C. Mamo

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Background: While antipsychotic-free schizophrenia patients showed a high degree of within-subject variability in dopamine D₂ receptor density over 6-24 months, no study has examined the long-term stability of D₂ receptor measures in medicated patients. Methods: Four schizophrenia patients receiving a stable dose of risperidone underwent [¹¹C]raclopride positron emission tomography scans on two occasions 5-14 months apart. Results: Plasma risperidone levels were found to be consistent between scans, and consistencies of nondisplaceable D₂ binding potential and D₂ occupancy were good. Conclusions: The finding supports the validity of quantification of D₂ receptor binding in longitudinal PET studies of medicated patients with schizophrenia.

Original language	English
Pages (from-to)	130-133
Number of pages	4
Journal	Schizophrenia Research
Volume	109
Issue number	1-3
DOIs	https://doi.org/10.1016/j.schres.2008.12.022
Publication status	Published - 2009 Apr
Externally published	Yes

Keywords

Antipsychotic
Dopamine
Dopamine D receptor
PET
Risperidone
Schizophrenia

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.schres.2008.12.022

Cite this

@article{5912fe645acf4034aa712142358ea31f,

title = "Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics",

abstract = "Background: While antipsychotic-free schizophrenia patients showed a high degree of within-subject variability in dopamine D2 receptor density over 6-24 months, no study has examined the long-term stability of D2 receptor measures in medicated patients. Methods: Four schizophrenia patients receiving a stable dose of risperidone underwent [11C]raclopride positron emission tomography scans on two occasions 5-14 months apart. Results: Plasma risperidone levels were found to be consistent between scans, and consistencies of nondisplaceable D2 binding potential and D2 occupancy were good. Conclusions: The finding supports the validity of quantification of D2 receptor binding in longitudinal PET studies of medicated patients with schizophrenia.",

keywords = "Antipsychotic, Dopamine, Dopamine D receptor, PET, Risperidone, Schizophrenia",

author = "Hiroyuki Uchida and Ariel Graff-Guerrero and Mulsant, {Benoit H.} and Pollock, {Bruce G.} and Mamo, {David C.}",

note = "Funding Information: Dr. Pollock has received grants or research support from the National Institute of Health and Janssen Pharmaceuticals. He has served on the advisory board of Forest Laboratories and is a faculty member of the Lundbeck Institute. He is on the speakers' bureau of Forest and Lundbeck. Funding Information: Dr. Mamo has received grants, consultant fees, or other financial support from the Canadian Psychiatric Research Foundation, the Schizophrenia Society of Canada, the Stanley Medical Research Institute, and Bristol-Myers Squibb, and has received speaker's honoraria from AstraZeneca within the past 5 years. Funding Information: Dr. Uchida's fellowship has been supported by the Japanese Society of Clinical Neuropsychopharmacology, Pfizer Health Research Foundation, and Mochida Memorial Foundation and received speaker's honoraria or manuscript fees from GlaxoSmithKline, Otsuka, and Dainippon Sumitomo Pharma within the past 5 years. ",

year = "2009",

month = apr,

doi = "10.1016/j.schres.2008.12.022",

language = "English",

volume = "109",

pages = "130--133",

journal = "Schizophrenia Research",

issn = "0920-9964",

publisher = "Elsevier",

number = "1-3",

}

TY - JOUR

T1 - Long-term stability of measuring D2 receptors in schizophrenia patients treated with antipsychotics

AU - Uchida, Hiroyuki

AU - Graff-Guerrero, Ariel

AU - Mulsant, Benoit H.

AU - Pollock, Bruce G.

AU - Mamo, David C.

N1 - Funding Information: Dr. Pollock has received grants or research support from the National Institute of Health and Janssen Pharmaceuticals. He has served on the advisory board of Forest Laboratories and is a faculty member of the Lundbeck Institute. He is on the speakers' bureau of Forest and Lundbeck. Funding Information: Dr. Mamo has received grants, consultant fees, or other financial support from the Canadian Psychiatric Research Foundation, the Schizophrenia Society of Canada, the Stanley Medical Research Institute, and Bristol-Myers Squibb, and has received speaker's honoraria from AstraZeneca within the past 5 years. Funding Information: Dr. Uchida's fellowship has been supported by the Japanese Society of Clinical Neuropsychopharmacology, Pfizer Health Research Foundation, and Mochida Memorial Foundation and received speaker's honoraria or manuscript fees from GlaxoSmithKline, Otsuka, and Dainippon Sumitomo Pharma within the past 5 years.

PY - 2009/4

Y1 - 2009/4

N2 - Background: While antipsychotic-free schizophrenia patients showed a high degree of within-subject variability in dopamine D2 receptor density over 6-24 months, no study has examined the long-term stability of D2 receptor measures in medicated patients. Methods: Four schizophrenia patients receiving a stable dose of risperidone underwent [11C]raclopride positron emission tomography scans on two occasions 5-14 months apart. Results: Plasma risperidone levels were found to be consistent between scans, and consistencies of nondisplaceable D2 binding potential and D2 occupancy were good. Conclusions: The finding supports the validity of quantification of D2 receptor binding in longitudinal PET studies of medicated patients with schizophrenia.

AB - Background: While antipsychotic-free schizophrenia patients showed a high degree of within-subject variability in dopamine D2 receptor density over 6-24 months, no study has examined the long-term stability of D2 receptor measures in medicated patients. Methods: Four schizophrenia patients receiving a stable dose of risperidone underwent [11C]raclopride positron emission tomography scans on two occasions 5-14 months apart. Results: Plasma risperidone levels were found to be consistent between scans, and consistencies of nondisplaceable D2 binding potential and D2 occupancy were good. Conclusions: The finding supports the validity of quantification of D2 receptor binding in longitudinal PET studies of medicated patients with schizophrenia.

KW - Antipsychotic

KW - Dopamine

KW - Dopamine D receptor

KW - PET

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=62949142048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62949142048&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2008.12.022

DO - 10.1016/j.schres.2008.12.022

M3 - Article

C2 - 19179049

AN - SCOPUS:62949142048

SN - 0920-9964

VL - 109

SP - 130

EP - 133

JO - Schizophrenia Research

JF - Schizophrenia Research

IS - 1-3

ER -